Keyword: Boehringer Ingelheim
As sales of blockbuster lung drug Spiriva flagged in 2018, Boehringer Ingelheim needed a boost from other divisions. Turns out diabetes was the key.
Boehringer Ingelheim talks about its winning strategy for IPF treatment Ofev as the winner of #FierceMadness DTC 2019.
Boehringer Ingelheim brings its two business units together in a new corporate campaign centered on the unique bond between patients and animals.
Boehringer Ingelheim’s ad campaign for Ofev pulled away from GlaxoSmithKline’s Trelegy to land the #FierceMadness ad tournament crown.
The #FierceMadness final game is set—and it’ll be GlaxoSmithKline's Trelegy taking on Boehringer Ingelheim's Ofev for the 2019 title.
AbbVie investors are calling for a separation of powers between its board chairman and CEO roles following congressional scrutiny and patent fights over its drug Humira.
#FierceMadness DTC is down to Repatha versus Trelegy, while Aimovig will take on Ofev in a short round of voting that ends Tuesday at midnight.
And then there were eight. The #FierceMadness Elite Eight bracket is set, with six brand-name drugs and two awareness campaigns still in the running.
Increased incidence of diabetic ketoacidosis in Type 1 patients, an issue raised at Zynquista's AdCom meeting, has shown up in other SGLT trials.
Analysts with Cortellis expect seven blockbuster drug launches in markets across the world this year. AbbVie's upadacitinib leads the pack.